Literature DB >> 7682536

Inhibition of LFA-1-dependent human B-cell aggregation induced by CD40 antibodies and interleukin-4 leads to decreased IgE synthesis.

P Björck1, S Paulie.   

Abstract

Antibodies to CD40 have been shown to induce homotypic aggregation of human resting B cells and B-cell lines via an LFA-1-dependent mechanism. We show here that interleukin-4 (IL-4) is a strong potentiator of this process and stimulation of tonsillar B cells for 4 days with IL-4 and CD40 antibodies resulted in the formation of large, dense aggregates. Also in this case, aggregation appeared to be chiefly dependent on the activation of LFA-1, although the small clusters of cells remaining after blocking with LFA-1 antibodies suggest the involvement of another adhesion system(s). When testing the relationship between aggregation and IgE synthesis, a known consequences of IL-4/CD40 stimulation, IgE levels were found to be significantly decreased in the presence of LFA-1 antibodies. In contrast to these observations, proliferation occurring in response to the IL-4/CD40 stimulation was not inhibitable by LFA-1 antibodies. Rather, in most cases, this was slightly enhanced, suggesting that aggregation may have a limiting effect on cell growth. Isolated aggregates, each of which could comprise more than 10(5) cells, were also examined by electron microscopy. This revealed a tissue-like structure of the aggregates with large contact areas and with minimal intercellular space between the adjacent cells. As the apparent inhibitory effect of aggregation on proliferation may reflect a negative autocrine signalling, which is enhanced by the close cell contact, we also tested the effect of neutralizing antibodies to IL-6, one of the factors known to be produced in the system. Such treatment did not affect aggregation but in most experiments enhanced proliferation. The results suggest that a possible effect of aggregation may be to enhance differentiation of cells and that this may also be associated with the difficulties in growing B cells in vitro.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7682536      PMCID: PMC1421796     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  23 in total

1.  Transmembrane signals generated through MHC class II, CD19, CD20, CD39, and CD40 antigens induce LFA-1-dependent and independent adhesion in human B cells through a tyrosine kinase-dependent pathway.

Authors:  G S Kansas; T F Tedder
Journal:  J Immunol       Date:  1991-12-15       Impact factor: 5.422

2.  Growing human B lymphocytes in the CD40 system.

Authors:  J Banchereau; F Rousset
Journal:  Nature       Date:  1991-10-17       Impact factor: 49.962

3.  A monoclonal antibody against altered LFA-1 induces proliferation and lymphokine release of cloned T cells.

Authors:  H Pircher; P Groscurth; S Baumhütter; M Aguet; R M Zinkernagel; H Hengartner
Journal:  Eur J Immunol       Date:  1986-02       Impact factor: 5.532

4.  Induction of aggregation and enhancement of proliferation and IL-2 secretion in human T cells by antibodies to CD43.

Authors:  B Axelsson; R Youseffi-Etemad; S Hammarström; P Perlmann
Journal:  J Immunol       Date:  1988-11-01       Impact factor: 5.422

5.  The human B lymphocyte and carcinoma antigen, CDw40, is a phosphoprotein involved in growth signal transduction.

Authors:  S Paulie; A Rosén; B Ehlin-Henriksson; S Braesch-Andersen; E Jakobson; H Koho; P Perlmann
Journal:  J Immunol       Date:  1989-01-15       Impact factor: 5.422

6.  Induction of CD43 expression during activation and terminal differentiation of human B cells.

Authors:  M Wikén; P Björck; B Axelsson; P Perlmann
Journal:  Scand J Immunol       Date:  1988-10       Impact factor: 3.487

7.  Resting B lymphocytes can be triggered directly through the CDw40 (Bp50) antigen. A comparison with IL-4-mediated signaling.

Authors:  J Gordon; M J Millsum; G R Guy; J A Ledbetter
Journal:  J Immunol       Date:  1988-03-01       Impact factor: 5.422

8.  Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1).

Authors:  S D Marlin; T A Springer
Journal:  Cell       Date:  1987-12-04       Impact factor: 41.582

9.  Interleukin-4-mediated aggregation of anti-IgM-stimulated human B cells: inhibition of aggregation but enhancement of proliferation by antibodies to LFA-1.

Authors:  P Björck; S Paulie; B Axelsson
Journal:  Immunology       Date:  1992-01       Impact factor: 7.397

10.  Intercellular adhesion molecule 3, a third adhesion counter-receptor for lymphocyte function-associated molecule 1 on resting lymphocytes.

Authors:  A R de Fougerolles; T A Springer
Journal:  J Exp Med       Date:  1992-01-01       Impact factor: 14.307

View more
  5 in total

1.  CD40 antibodies defining distinct epitopes display qualitative differences in their induction of B-cell differentiation.

Authors:  P Björck; S Paulie
Journal:  Immunology       Date:  1996-02       Impact factor: 7.397

2.  Two differently regulated nuclear factor kappaB activation pathways triggered by the cytoplasmic tail of CD40.

Authors:  N Tsukamoto; N Kobayashi; S Azuma; T Yamamoto; J Inoue
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

3.  Epstein-Barr virus infection negatively impacts the CXCR4-dependent migration of tonsillar B cells.

Authors:  Barbro Ehlin-Henriksson; Frida Mowafi; George Klein; Anna Nilsson
Journal:  Immunology       Date:  2006-03       Impact factor: 7.397

4.  Antibodies to distinct epitopes on the CD40 molecule co-operate in stimulation and can be used for the detection of soluble CD40.

Authors:  P Björck; S Braesch-Andersen; S Paulie
Journal:  Immunology       Date:  1994-11       Impact factor: 7.397

5.  Efficient antigen presentation of soluble, but not particulate, antigen in the absence of Wiskott-Aldrich syndrome protein.

Authors:  Lisa Westerberg; Robert P A Wallin; Gediminas Greicius; Hans-Gustaf Ljunggren; Eva Severinson
Journal:  Immunology       Date:  2003-07       Impact factor: 7.397

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.